Cariprazine

• Schizophrenia
• Bipolar I Disorder
• Bipolar Depression
• Major Depressive Disorder (adjunct)

Cariprazine is an atypical antipsychotic medication approved for the treatment of schizophrenia, bipolar I disorder, and major depressive disorder. This medication has a unique pharmacological profile with preferential binding to dopamine D3 receptors, which may contribute to its efficacy in treating negative symptoms and cognitive deficits.

Mechanism of Action

Cariprazine is a dopamine D3 and D2 receptor partial agonist with preferential binding to D3 receptors. It also acts as a partial agonist at serotonin 5-HT1A receptors and an antagonist at 5-HT2B and 5-HT2A receptors. The D3 receptor preference is approximately 10-fold higher than D2, which distinguishes cariprazine from other antipsychotics. D3 receptors are concentrated in limbic regions involved in motivation, emotion, and cognition. The partial agonist activity provides stabilization of dopamine signaling, potentially improving positive, negative, and cognitive symptoms while minimizing extrapyramidal side effects.

Available Formulations

Cariprazine is available as oral capsules in 1.5 mg, 3 mg, 4.5 mg, and 6 mg strengths. The capsules can be taken with or without food. Due to the medication's long half-life (including active metabolites with half-lives of 1-3 weeks), dose adjustments should be made at intervals of at least 2 weeks.

Medical Uses

Cariprazine is FDA-approved for the treatment of schizophrenia in adults, acute treatment of manic or mixed episodes associated with bipolar I disorder in adults, depressive episodes associated with bipolar I disorder (bipolar depression) in adults, and as adjunctive treatment for major depressive disorder (MDD) in adults. Clinical trials demonstrated improvement in negative symptoms of schizophrenia, which is often difficult to treat with other antipsychotics.

Dosing Guidelines

For schizophrenia, the recommended dose range is 1.5-6 mg once daily, starting at 1.5 mg on day 1, and can be increased to 3 mg on day 2, with further adjustments in 1.5-3 mg increments based on response and tolerability. For bipolar mania, dosing is similar with a range of 3-6 mg daily. For bipolar depression, the recommended dose is 1.5 mg daily, increased to 3 mg on day 15 based on response. For MDD adjunctive therapy, start at 1.5 mg daily with potential increase to 3 mg. Dose adjustment is needed with CYP3A4 inhibitors.

Important Safety Information

Cariprazine carries a boxed warning regarding increased mortality in elderly patients with dementia-related psychosis (not approved for this use) and increased risk of suicidal thoughts and behaviors in patients under 24 with MDD. Other serious risks include neuroleptic malignant syndrome, tardive dyskinesia, metabolic changes, orthostatic hypotension, falls, leukopenia/neutropenia, seizures, and potential cognitive and motor impairment. The long half-life means adverse effects may take weeks to resolve after discontinuation.

Drug Interactions

Strong CYP3A4 inhibitors (ketoconazole, itraconazole, clarithromycin) increase cariprazine levels; dose should be reduced by half if used with these agents. Strong CYP3A4 inducers (rifampin, carbamazepine, phenytoin) may substantially decrease levels; concomitant use is not recommended. Moderate CYP3A4 inhibitors may require dose adjustment. Due to the long half-life, it may take several weeks for interactions to manifest or resolve.

Where Cariprazine Fits Among Related Agents

Cariprazine belongs to the same small family as aripiprazole and brexpiprazole — dopamine partial agonists rather than pure receptor blockers — and the practical case for it usually rests on one of three things. The first is negative symptoms of schizophrenia, the blunting, withdrawal, and loss of drive that respond poorly to most antipsychotics; cariprazine has trial data in that domain that its peers largely lack. The second is the depressive pole of bipolar disorder, where it is approved for bipolar I depression alongside a small number of alternatives such as lurasidone and quetiapine, and where antidepressant monotherapy is avoided because of the risk of switching a patient into mania. The third is add-on treatment in major depressive disorder that has only partly responded to an antidepressant.

Against it are akathisia, which is more common than with several alternatives and is the usual reason patients stop, and the metabolic profile shared by the class. Where a patient needs sedation at night, quetiapine may suit better; where weight gain must be minimized, lurasidone and the partial agonists are generally preferred over olanzapine. Lithium and lamotrigine remain the maintenance mood stabilizers against which any antipsychotic in bipolar disorder is measured.

The Long Half-Life Changes How It Is Used

Cariprazine and its active metabolites persist far longer than most oral psychiatric medications, and almost every practical rule about the drug follows from that. Dose increases are spaced widely apart, because the blood level that follows a change keeps rising for weeks; a clinician who titrates on a weekly rhythm out of habit will overshoot. Benefit is judged on the same slow clock, so a trial that would be called a failure at two weeks with another agent is simply incomplete here. The same applies in reverse: a side effect that appears after a dose increase may take several weeks to settle after the dose is reduced, and stopping the drug does not clear it quickly. Patients should be told this in advance so that a delayed improvement is not mistaken for the drug never having worked.

Restlessness in the early weeks is worth asking about directly rather than waiting for it to be reported, because patients often describe it as anxiety or as the illness worsening; reducing the dose or slowing the titration usually resolves it. Metabolic parameters — weight, blood pressure, fasting glucose or A1c, and lipids — are measured before starting and rechecked periodically, most closely during the first year. Movements are examined at each visit for early signs of tardive dyskinesia. Because the drug is metabolized by CYP3A4, a new prescription for a strong inhibitor or inducer changes exposure substantially and should prompt a dose review rather than being noticed later as a side effect. The MedlinePlus cariprazine monograph covers the patient-facing details, and the NIMH overview of bipolar disorder explains where medication sits in the overall treatment plan. Our psychiatric colleagues share this monitoring with the primary care team.

Special Populations

There are limited data on use during pregnancy; neonates exposed to antipsychotics during the third trimester may experience extrapyramidal or withdrawal symptoms. Cariprazine and its metabolites are present in rat milk; breastfeeding is not recommended. Safety and efficacy have not been established in pediatric patients. Clinical trials included limited elderly patients; no overall differences in safety were observed but increased sensitivity is possible. No dose adjustment is needed for mild to moderate renal or hepatic impairment; use is not recommended in severe impairment.